Strong Buyers of Pharmacyclics (PCYC) Into Q1 Results and ASCO - Baird

Baird analyst Brian Skorney reiterated an Outperform rating and $173 price target on Pharmacyclics (NASDAQ: PCYC) saying they are strong buyers of the stock into 1Q14 earnings and ASCO.

Skorney said, "After blowing away 4Q13 estimates, Pharmacyclics is looking to keep the momentum rolling after a full quarter of Imbruvica sales when it reports first-quarter results May 2. As one of our top picks for the year, we are confident that Imbruvica will perform well again this quarter after analyzing script trends. PCYC will also be a main participant at ASCO this year with RESONATE data as one of the conference's headliners."

For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.

Shares of Pharmacyclics closed at $91.70 yesterday.

You May Also Be Interested In

• Goldman Sachs on Meta Platforms Inc. (META): 'We expect investors to have an initial negative reaction'
• Alamos Gold (AGI) Misses Q1 EPS by 1c
• Ternium SA (TX) Tops Q1 EPS by 17c